复星医药(02196.HK):供港疫苗紧急使用认可有效期12个月
复星医药(02196.HK)表示,控股子公司上海复星医药产业发展与德国BioNTech SE合作的mRNA新冠疫苗疫苗产品,於1月25日获香港特别行政区认可於香港紧急使用,紧急使用认可有效期为12个月,可依据香港《预防及控制疾病(使用疫苗)规例》(第599K章)被进一步延长期限或被撤销。
该疫苗在中国大陆尚处於II期临床试验阶段,目前区内尚未有其他基於mRNA技术平台研发的针对新型冠状病毒的预防性疫苗获准上市或紧急使用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.